Scheurleer Willem Frederik Julius, de Ridder Mischa, Tagliaferri Luca, Crescio Claudia, Parrilla Claudio, Mattiucci Gian Carlo, Fionda Bruno, Deganello Alberto, Galli Jacopo, de Bree Remco, Rijken Johannes A, Bussu Francesco
Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Cancers (Basel). 2023 Dec 20;16(1):37. doi: 10.3390/cancers16010037.
Squamous cell carcinoma of the nasal vestibule is considered a rare malignancy that differs from other sinonasal malignancies in many respects. Four staging systems currently exist for this disease, the most recent addition being the "Rome" classification. This study assesses the use of this new classification and its prognostic value regarding various outcome measures. A retrospective multicenter cohort study of patients with a primary squamous cell carcinoma of the nasal vestibule who were treated in three tertiary head and neck oncology referral centers was conducted. A total of 149 patients were included. The median follow-up duration was 27 months. Five-year locoregional control (LRC), disease-specific survival (DSS), and overall survival (OS) were 81.6%, 90.1, and 62.5% respectively. A statistically significant association was observed between the Rome classification and all survival outcomes in both univariable and multivariable analyses. Moreover, it appeared to perform better than the Union for International Cancer Control TNM classification for tumors of the nasal cavity and paranasal sinuses. The new Rome classification can be used effectively and is associated with LRC, DSS, and OS. However, it requires further validation in a larger (prospective) study population.
鼻前庭鳞状细胞癌被认为是一种罕见的恶性肿瘤,在许多方面与其他鼻窦恶性肿瘤不同。目前针对该疾病存在四种分期系统,最新增加的是“罗马”分类。本研究评估了这种新分类的应用及其对各种预后指标的预后价值。对在三个三级头颈肿瘤转诊中心接受治疗的原发性鼻前庭鳞状细胞癌患者进行了一项回顾性多中心队列研究。共纳入149例患者。中位随访时间为27个月。5年局部区域控制率(LRC)、疾病特异性生存率(DSS)和总生存率(OS)分别为81.6%、90.1%和62.5%。在单变量和多变量分析中,均观察到罗马分类与所有生存结局之间存在统计学显著关联。此外,对于鼻腔和鼻窦肿瘤,它似乎比国际癌症控制联盟TNM分类表现更好。新的罗马分类可以有效使用,并且与LRC、DSS和OS相关。然而,它需要在更大的(前瞻性)研究人群中进一步验证。